After Birth,Apparent Diffusion Coefficient,Apparent Diffusion Coefficient Values,Basis For Diagnosis,Brain Cells,Brain Edema,Brain Injury,Brain Tissue,Cytotoxic Edema,Degree Of Injury,Early ...

Eli Lilly & Co. said that a small change in dosing its Alzheimer’s drug Kisunla cut patients’ rate of brain-swelling side effects in preliminary results from a study. A more gradual increase ...

At week 24 of the year-long study, 14% of patients with early-stage Alzheimer's who received a lower starting dose of the monthly infusion had the brain swelling side effect known as ARIA-E.

Nov. 18, 2024 — Scientists reveal how sleep, especially naps, boosts motor learning after TBI, offering new insights into brain activity and rehabilitation strategies to enhance recovery ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain swelling of patients in a late-stage trial following an adjusted dosing ...

CHICAGO (Reuters) - Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to ...

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in a trial, the company said Tuesday. In the phase 3 study ...

Opens in a new tab or window An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction ...

In this work, the authors propose that astrocytic aquaporin 4 (AQP4) is the main pathway for tonic water efflux, without which astrocytes undergo cell swelling. These findings are important, because ...

The researchers identified 12 eyes of 7 patients (mean age, 73.3 years; 4 women) with noninfectious IOI after intravitreal faricimab injections.